Attovia Therapeutics To Participate In Upcoming Investor Conferences
Guggenheim 3 rd Annual Healthcare Innovation Conference
Format: Fireside chat
Date: Tuesday, November 10, 2026
Time: 3:30 PM - 3:55 PM ET
Stifel 2026 Healthcare Conference
Format: 1x1 Meetings
Date: Wednesday, November 11, 2026
2026 Jefferies Global Healthcare Conference in London
Format: 1x1 Meetings
Date: Monday, November 16 – Wednesday, November 18, 2026
The webcast of the Guggenheim fireside chat will be available in the“Events & Presentations” section of Attovia's website at . A replay of the webcast will be available for approximately 90 days following the conference.
About Attovia Therapeutics, Inc.
AttoviaTM is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODYTM biparatopic biologics platform. Attovia's ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.
Attovia's lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia's other programs include highly innovative conditional 'AND' gated bispecific immune cell survival blockers and multispecifics.
Investor and Media Contact
Attovia Therapeutics
...
PJ Kelleher
LifeSci Advisors LLC
617-430-7579
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment